Why Is Celcuity (CELC) Stock Down -22% Today?

Key Takeaways

• CELC shares are falling sharply in premarket trading on June 2, 2026, declining approximately 22% from the prior session's close of $126.18, implying a premarket price near $98.42
• The primary catalyst is the full detailed data presentation from the PIK3CA mutant cohort of Celcuity's Phase 3 VIKTORIA-1 clinical trial, delivered at the ASCO Annual Meeting in Chicago on June 2 — a long-anticipated event that appears to have triggered a "sell the news" reaction
• The stock had already rallied dramatically in the months leading up to today on positive topline data, leaving shares particularly vulnerable to a sentiment reversal once concrete details were disclosed
• Broader biotech sector volatility around major clinical data readouts adds to the pressure, as investors reassess risk/reward after an extended run-up
• The FDA's PDUFA decision for gedatolisib in the PIK3CA wild-type indication, expected by July 17, 2026, remains the next significant regulatory milestone traders are monitoring

Opening Summary

Celcuity Inc. (CELC) is a Minneapolis-based clinical-stage biotechnology company focused on developing targeted cancer therapies, most notably gedatolisib, a pan-PI3K and mTORC1/2 inhibitor being evaluated for hormone receptor-positive, HER2-negative advanced breast cancer. Shares are down approximately 22% in Tuesday premarket trading, falling from a prior close of $126.18 to an implied level near $98.42. The steep decline follows the presentation of detailed Phase 3 VIKTORIA-1 data at the ASCO Annual Meeting, an event the market had long anticipated and which now appears to have catalyzed significant profit-taking and recalibration of investor expectations.

ASCO Data Presentation and "Sell the News" Dynamics

Celcuity had announced topline results from the PIK3CA mutant cohort of VIKTORIA-1 on April 30, 2026, confirming that the gedatolisib triplet and doublet regimens achieved statistically significant and clinically meaningful improvements in progression-free survival versus alpelisib plus fulvestrant. That announcement sent shares sharply higher, as did prior trial readouts, contributing to a stock that had rallied over 1,000% over the preceding twelve months. The full granular data — including precise hazard ratios, median PFS numbers by arm, subgroup analyses, and a complete safety breakdown — were reserved for the June 2 late-breaking abstract oral session at ASCO. When detailed data is dissected in real time by oncologists, investors, and analysts, even technically positive results can disappoint when specific metrics fail to clear the bar that a dramatically re-rated stock has priced in.

Clinical Data Context

The VIKTORIA-1 trial's PIK3CA mutant cohort evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR+/HER2- locally advanced or metastatic breast cancer who had progressed on prior CDK4/6 inhibitor and aromatase inhibitor therapy. Both the triplet and doublet regimens demonstrated statistically significant PFS improvement over alpelisib and fulvestrant, and both were generally well tolerated with no new safety signals. However, comparisons within the biotech investment community scrutinize not just statistical significance but effect size, comparator arm selection, and how data stacks up relative to competing agents — factors that become fully visible only at an ASCO presentation, and can recalibrate even a clinically meaningful outcome into a relative disappointment against the market's elevated pricing.

Market Context and Trading Activity

CELC's prior close of $126.18 already reflected substantial speculative premium built up over months of anticipatory trading ahead of ASCO. Volume on June 1 was notably subdued at 753,136 shares versus an average of approximately 870,000, suggesting many investors had already positioned ahead of the event and were poised to react swiftly to the data. Biotech stocks tied to late-stage oncology readouts historically experience exaggerated post-ASCO moves — both up and down — because the event represents the culmination of a long-building news cycle, leaving the stock with limited near-term catalysts to sustain valuation once the data is public. Broader biotech sector ETFs and peers with similar PAM-pathway or breast cancer exposure may face sympathetic pressure as the market reassesses the competitive landscape.

Trending AI Robots

For traders navigating high-volatility events like clinical data readouts, Tickeron's Trending AI Robots page offers a curated view of the platform's best-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-driven bots covering thousands of tickers across multiple strategies, timeframes, and asset classes, but only the top performers — ranked by recent metrics — appear in this Trending section. Bots vary widely in their approach, from momentum and swing strategies to mean-reversion and sector rotation, with each designed for a specific market environment. Traders looking to complement their own research with algorithmic tools may find this resource a useful starting point.

What Comes Next for CELC

The most immediate catalyst on the horizon is the FDA's PDUFA decision date for gedatolisib in the PIK3CA wild-type HR+/HER2- advanced breast cancer indication, expected by July 17, 2026 — a distinct regulatory milestone from today's mutant-cohort data. Approval would mark gedatolisib's first commercial launch and could materially alter the company's trajectory, while a Complete Response Letter would likely extend the sell-off. For the PIK3CA mutant indication, Celcuity has stated it intends to submit a supplemental New Drug Application (sNDA) to the FDA using today's VIKTORIA-1 data, with submissions to other regulatory authorities to follow. The next earnings report is scheduled for August 13, 2026, where management is expected to address pipeline progress and cash runway. CELC remains a pre-revenue, clinical-stage company reporting consistent net losses — $52.8 million in Q1 2026 alone — making it highly sensitive to trial outcomes and regulatory decisions. Analyst price targets and ratings revisions following the ASCO presentation will be closely watched in the sessions ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Contributor

Arthur Evans|Expert

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume